On November 21st, the launch conference of the fourth generation solid-state nanopore gene detector engineering prototype of Suzhou Linaxin Biotechnology Co., Ltd. was held at Huaqiao International Innovation Port.

As a tool for life science research, solid-state nanopore gene detectors play a high-precision role in animal, microbial, plant, environmental, human, clinical research, and other fields. Secondly, in the clinical medical field, they have great advantages in precision prevention, early screening, accurate diagnosis, cancer early screening, rapid detection of pathogenic microorganisms, and rapid reporting of clinical tests.

At the press conference, Dr. Zhu, Chief Technology Officer of Linaxin, explained and presented the principle, system composition, testing process, and testing data of the new generation of testing instrument engineering prototype.

This prototype completes the entire detection process automatically through a "voltage feedback control" approach, without the need for other manual operations except for adding the test sample, and has a very high degree of automation.

Linaxin has formulated a three-step strategic plan. The first step is to further optimize the opening current noise, current stability, data analysis algorithm, fluid chip opening rate and other issues based on the framework of the prototype already launched. It will take about a year, around July 2024, to launch the first domestic solid-state nanopore gene detector product for the life science research market. On this basis, it will take another 1-2 years to launch a high-throughput and highly integrated detection instrument for the clinical medicine market. Based on a clear technical roadmap, after subsequent optimization, the instrument's final detection accuracy can reach over 99%, achieving high-throughput, highly integrated, low-cost, and large-scale detection of target substances.